{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:00:14Z","timestamp":1760853614617,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.brainres.2012.06.037","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T21:02:04Z","timestamp":1341522124000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor"],"prefix":"10.1016","volume":"1470","author":[{"given":"Nibha","family":"Mishra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinakar","family":"Sasmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2012.06.037_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjp.0705962","article-title":"Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline","volume":"143","author":"Abassi","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0278-5846(02)00340-8","article-title":"Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione\/reduced glutathione ratio (GSSG\/GSH) enhancement in rats","volume":"27","author":"Ab\u00edlio","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2012.06.037_bib3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/jpet.103.064782","article-title":"SL25. 1131 [3 (S), 3a (S)-3-Methoxymethyl-7-[4, 4, 4-trifluorobutoxy]-3, 3a, 4, 5-tetrahydro-1, 3-oxazolo [3, 4-a] quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile","volume":"310","author":"Aubin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2012.06.037_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","article-title":"Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders","volume":"9","author":"Binda","year":"2001","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.brainres.2012.06.037_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.brainres.2012.06.037_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(75)90238-1","article-title":"The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation","volume":"34","author":"Braestrup","year":"1975","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0272-0590(85)90059-4","article-title":"An up-and-down procedure for acute toxicity testing","volume":"5","author":"Bruce","year":"1985","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.brainres.2012.06.037_bib8","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1471-4159.1980.tb11267.x","article-title":"Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain","volume":"34","author":"Burden","year":"1980","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2012.06.037_bib9","first-page":"259","article-title":"Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases","volume":"41","author":"Delumeau","year":"1994","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2012.06.037_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0028-3908(02)00216-2","article-title":"Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours","volume":"43","author":"Finberg","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2012.06.037_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/med.2610040303","article-title":"Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties","volume":"4","author":"Fowler","year":"1984","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.brainres.2012.06.037_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01249185","article-title":"The effect of age on the activity and molecular properties of human brain monoamine oxidase","volume":"49","author":"Fowler","year":"1980","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2012.06.037_bib12","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/0006-2952(80)90012-X","article-title":"A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxy amphetamine and harmaline","volume":"29","author":"Green","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib32","first-page":"73","article-title":"Assessment of the potency of reversible MAO inhibitors in vivo","author":"Green","year":"1984"},{"key":"10.1016\/j.brainres.2012.06.037_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/abio.1996.9911","article-title":"A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates","volume":"244","author":"Holt","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.brainres.2012.06.037_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0006-2952(64)90154-6","article-title":"An analysis of the interaction of reversible and irreversible monoamine oxidase inhibitors","volume":"13","author":"Horita","year":"1964","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.1964.03060390010002","article-title":"Monoamine oxidase inhibitors, tyramine, and cheese","volume":"188","author":"Horwitz","year":"1964","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.brainres.2012.06.037_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bjp.0702389","article-title":"Effect of low dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine induced dopamine release in vivo","volume":"126","author":"Lamensdorf","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0022-3565(24)38016-4","article-title":"l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine","volume":"288","author":"Melega","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2012.06.037_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.bmcl.2011.02.030","article-title":"Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation","volume":"21","author":"Mishra","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2012.06.037_bib19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)35352-2","article-title":"FA-70, a novel selective and irreversible monoamine oxidase-A inhibitor: effect on monoamine metabolism in mouse cerebral cortex","volume":"292","author":"Mor\u00f3n","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2012.06.037_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00432018","article-title":"Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors","volume":"84","author":"Ortmann","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2012.06.037_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0197-0186(02)00091-8","article-title":"PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57\/BL6 mice","volume":"42","author":"Perez","year":"2003","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.brainres.2012.06.037_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0197-4580(84)90038-1","article-title":"Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine","volume":"5","author":"Ponzio","year":"1984","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.brainres.2012.06.037_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10787-007-1614-0","article-title":"Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice","volume":"16","author":"Rajeswari","year":"2008","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.brainres.2012.06.037_bib24","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.2174\/092986711797636090","article-title":"The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant\/anticonvulsant agents","volume":"18","author":"Secci","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.brainres.2012.06.037_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","article-title":"Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent","volume":"25","author":"Sedlak","year":"1968","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.brainres.2012.06.037_bib26","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.67.7_suppl_2.S24","article-title":"Symptom relief in Parkinson disease by safinamide","volume":"67","author":"Stocchi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2012.06.037_bib33","first-page":"155","article-title":"The inhibition of rat liver monoamine oxidase-B by the enantiomers of MD 780236","author":"Tipton","year":"1984"},{"key":"10.1016\/j.brainres.2012.06.037_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01244780","article-title":"Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects","volume":"74","author":"Turkish","year":"1988","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2012.06.037_bib34","first-page":"108","article-title":"Reversible monoamine oxidase inhibitors: relation between effects on enzymatic activity measured ex vivo and on amine activity","author":"Waldmeier","year":"1984"},{"key":"10.1016\/j.brainres.2012.06.037_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2012.06.037_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N\u2010propargyl\u20101R (+)\u2010aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2012.06.037_bib30","first-page":"397","article-title":"Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications","volume":"41","author":"Yu","year":"1994","journal-title":"J. Neural Transm."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899312011122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899312011122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T17:49:57Z","timestamp":1757785797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899312011122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":34,"alternative-id":["S0006899312011122"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2012.06.037","relation":{},"ISSN":["0006-8993"],"issn-type":[{"type":"print","value":"0006-8993"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2012.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}